Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia.
Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia.
J Surg Res. 2021 Mar;259:154-162. doi: 10.1016/j.jss.2020.11.038. Epub 2020 Dec 3.
A significant percentage of patients who acutely develop high-grade atrioventricular block after valve surgery will ultimately recover, yet the ability to predict recovery is limited. The purpose of this analysis was to evaluate the cost-effectiveness of two different management strategies for the timing of permanent pacemaker implantation for new heart block after valve surgery.
A cost-effectiveness model was developed using costs and probabilities of short- and long-term complications of pacemaker placement, short-term atrioventricular node recovery, intensive care unit stays, and long-term follow-up. We aggregated the total expected cost and utility of each option over a 20-y period. Quality-adjusted survival with a pacemaker was estimated from the literature and institutional patient-reported outcomes. Primary decision analysis was based on an expected recovery rate of 36.7% at 12 d with timing of pacemaker implantation: early placement (5 d) versus watchful waiting for 12 d.
A strategy of watchful waiting was more costly ($171,798 ± $45,695 versus $165,436 ± $52,923; P < 0.0001) but had a higher utility (9.05 ± 1.36 versus 8.55 ± 1.33 quality-adjusted life years; P < 0.0001) than an early pacemaker implantation strategy. The incremental cost-effectiveness ratio of watchful waiting was $12,724 per quality-adjusted life year. The results are sensitive to differences in quality-adjusted survival and rates of recovery of atrioventricular node function.
Watchful waiting for pacemaker insertion is a cost-effective management strategy compared with early placement for acute atrioventricular block after valve surgery. Although this is cost-effective from a population perspective, clinical risk scores predicting recovery will aid in personalized decision-making.
相当一部分在瓣膜手术后急性发生高度房室传导阻滞的患者最终会康复,但目前预测其恢复能力的方法有限。本分析旨在评估瓣膜手术后新发心脏阻滞患者永久性起搏器植入时机的两种不同管理策略的成本效益。
采用成本和起搏器放置的短期和长期并发症、短期房室结恢复、重症监护病房停留和长期随访的概率,建立成本效益模型。我们汇总了 20 年内每种选择的总预期成本和效用。使用文献和机构患者报告的结果来估计带起搏器的质量调整生存。主要决策分析基于 12d 时 36.7%的预期恢复率,起搏器植入的时机:早期(5d)与 12d 时的观察等待。
观察等待策略的成本更高($171798±$45695 比 $165436±$52923;P<0.0001),但效用更高(9.05±1.36 比 8.55±1.33 质量调整生命年;P<0.0001),优于早期起搏器植入策略。观察等待策略的增量成本效益比为每质量调整生命年 12724 美元。结果对质量调整生存和房室结功能恢复率的差异敏感。
与早期起搏器植入相比,瓣膜手术后急性房室传导阻滞时,观察等待是一种具有成本效益的起搏器植入管理策略。尽管从人群角度来看这是具有成本效益的,但预测恢复的临床风险评分将有助于个性化决策。